Skip to main content

Advertisement

Table 1 Baseline clinical characteristics of the patients

From: The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells

  Number of patients (N = 32) Association with advance LTS score P value ± R 2, as applicable
Age (yrs) 65 ± 2 0.55
BMI 28 ± 1 0.35
Gender (%male) 66 % 0.56
Hypertension 71 % 0.09
Dyslipidemia 69 % 0.12
Current smoker 9 % 0.45*
Former smoker 34 %
Diabetes 34 % 0.0003
HbA1C 0.062 ± 0.01 0.002 (R 2 = 0.4)
Fasting glucose 6.2 ± 0.7 0.18
Thyroid or other endocrine disease 9 % 0.38
Peripheral vascular disease 25 % 0.13
History of MI 34 % 0.01
Valvular heart disease 56 % 0.09
Coronary artery disease 75 % 0.09
Congestive heart failure 16 % 0.28
NYHA class 1.6 ± 0.1 0.94
LV ejection fraction 54 ± 2 0.02 (R 2 = 0.17)
CCS class 1.9 ± 0.1 0.74
Creatinine (umol/L) 83 ± 3 0.14
Medications:
 Anti-platelet/Anti-coagulant 78 % 0.12
 Beta-blocker 56 % 0.38
 Statin 53 % 0.55
 Diuretics 31 % 0.07
 ACEI or ARB 46 % 0.11
 Calcium channel blocker 43 % 0.64
 Insulin 9 % 0.30
 Oral hypoglycemics 31 % <0.001
  1. LTS long term stratification, BMI body mass index, HbA1C hemoglobin A1c, MI myocardial infarction, NYHA New York Heart Association, LV left ventricle, CCS Canadian Cardiovascular Society, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers. *p vs. LTS score in non-smokers